PRME
NASDAQ · Biotechnology
Prime Medicine Inc
$4.72
-0.52 (-9.92%)
Open$5.02
Previous Close$5.24
Day High$5.20
Day Low$4.68
52W High$5.91
52W Low$2.67
Volume—
Avg Volume6.09M
Market Cap856.10M
P/E Ratio—
EPS$-1.09
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
+815.0% upside
Current
$4.72
$4.72
Target
$43.19
$43.19
$33.60
$43.19 avg
$71.66
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 7.25M | 5.54M | 80.41M |
| Net Income | -315,403,574 | -327,047,779 | -21,315,556 |
| Profit Margin | -4,342.4% | -6,238.3% | -26.5% |
| EBITDA | -315,240,286 | -345,948,669 | -26,154,771 |
| Free Cash Flow | — | — | -13,660,015 |
| Rev Growth | — | -17.0% | +23.7% |
| Debt/Equity | — | — | 0.50 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.34 | +1.08% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $461.10 | +0.18% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $168.18 | +0.36% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $546.92 | +0.81% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $908.12 | +0.58% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $157.53 | +0.56% | 28.8 | 23.28B |